Details

Autor(en) / Beteiligte

• Yuen, Man-Fung
• Agarwal, Kosh
• Ma, Xiaoli
• Nguyen, Tuan T.
• Schiff, Eugene R.
• Hann, Hie-Won L.
• Dieterich, Douglas T.
• Nahass, Ronald G.
• Park, James S.
• Chan, Sing
• Han, Steven-Huy B.
• Gane, Edward J.
• Bennett, Michael
• Alves, Katia
• Evanchik, Marc
• Yan, Ran
• Huang, Qi
• Lopatin, Uri
• Colonno, Richard
• Ma, Julie
• Knox, Steven J.
• Stamm, Luisa M.
• Bonacini, Maurizio
• Jacobson, Ira M.
• Ayoub, Walid S.
• Weilert, Frank
• Ravendhran, Natarajan
• Ramji, Alnoor
• Kwo, Paul Yien
• Elkhashab, Magdy
• Hassanein, Tarek
• Bae, Ho S.
• Lalezari, Jacob P.
• Fung, Scott K.
• Sulkowski, Mark S.

Titel

Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

Ist Teil von

• Journal of hepatology, 2022-09, Vol.77 (3), p.642-652

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppression when combined with NrtIs. This phase II trial (NCT03576066) evaluated the efficacy and safety of the investigational core inhibitor, vebicorvir (VBR), in virologically- suppressed patients on NrtIs. Non-cirrhotic, NrtI-suppressed patients with chronic HBV were randomised to VBR 300 mg once daily or matching placebo (PBO) for 24 weeks. Treatment was stratified by hepatitis B e antigen (HBeAg) status. The primary endpoint was change from Baseline in serum HBeAg or hepatitis B surface antigen (HBsAg) after 24 weeks. Of 73 patients enrolled, 47 were HBeAg positive and 26 were HBeAg negative. In HBeAg-positive and -negative patients, there were no differences in the change from Baseline at Week 24 for HBsAg or HBeAg. Using a novel, high-sensitivity assay to detect HBV DNA, a greater proportion of patients with detectable HBV DNA at Baseline achieved undetectable HBV DNA at Week 24 in the VBR+NrtI vs. PBO+NrtI group. In HBeAg-positive patients, a greater change from Baseline in HBV pregenomic (pg)RNA was observed at Week 24 with VBR+NrtI vs. PBO+NrtI. Treatment-emergent adverse events (TEAEs) in VBR+NrtI patients included upper respiratory tract infection, nausea, and pruritus. No serious adverse events, Grade 4 TEAEs, or deaths were reported. In this 24-week study, VBR+NrtI demonstrated a favourable safety and tolerability profile. While there were no significant changes in viral antigen levels, enhanced viral suppression was demonstrated by greater changes in DNA and pgRNA with the addition of VBR compared to NrtI alone. NCT03576066. Core inhibitors represent a novel approach for the treatment of chronic hepatitis B virus (HBV) infection, with mechanisms of action distinct from existing treatments. In this study, vebicorvir added to existing therapy reduced HBV replication to a greater extent than existing treatment and was generally safe and well tolerated. [Display omitted] •Complete suppression of HBV replication is essential for finite treatment regimens.•Vebicorvir (VBR) is a novel inhibitor of the HBV core protein.•VBR interferes with two additional steps in HBV replication than NrtIs.•Added to NrtI, VBR did not significantly change mean HBV antigens over 24 weeks.•Added to NrtI, VBR further reduced HBV DNA and pgRNA by high-sensitivity PCR assays.